Xenetic Biosciences, Inc. (XBIO) Form 10-Q — Aug 6, 2026
Xenetic Biosciences disclosed that its board has initiated a formal strategic review process with outside financial and legal advisors, weighing alternatives that include a sale of all or part of the company or a business combination such as a reverse merger. An independent board committee is in discussions with third parties, but there is no timetable or assurance of a deal, and any transaction could leave the counterparty's investors holding a substantial majority of the outstanding common stock.
Key figures
- Revenue
- 660601
- Revenue Yoy
- 12.0%
- Cash Position
- 6500000
- Shares Outstanding
- 2343181
- Total debt
- 0
- Ga expense q2
- 1080278
- Rd expense q2
- 552013
- Working capital
- 5800000
- Cash dec 31 2025
- 7900000
- Revenue six months
- 1467524
- Accumulated deficit
- 201300000
- Ga expense q2 change
- +64.2% (driven by strategic review legal costs)
- Rd expense q2 change
- -15.9%
- Revenue six months yoy
- 24.0%
- Total stockholders equity
- 6073021
- Net loss six months change
- -12.9% (improved vs prior year)
- Takeda royalty revenue six months
- 1500000
- Series b preferred converted to common shares
- 45000
- October 2025 underwritten offering net proceeds
- 4000000
Price after filing
Close on the filing date to close N calendar days later (from $2.96). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.